Entasis Therapeutics Garners $50,000,000 Series B Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=af8db5a7-600e-4f81-bba3-28aa4d799a4b - Date
4/5/2016 - Company Name
Entasis Therapeutics - Mailing Address
35 Gatehouse Drive Waltham, MA 02451 USA - Company Description
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases. - Website
http://www.entasistx.com - Transaction Type
Venture Equity - Transaction Amount
$50,000,000 - Transaction Round
Series B - Proceeds Purposes
The proceeds from this financing will enable us to further advance our portfolio of innovative anti-infective products directed at addressing the global health crisis created by the rise in antibiotic resistance in a fundamentally differentiated way. - M&A Terms
- Venture Investor
Clarus Ventures - Venture Investor
Frazier Healthcare Partners - Venture Investor
Novo Ventures - Venture Investor
Eventide Asset Management - Venture Investor
AstraZeneca
